Integra poised to take $60 million hit following voluntary recall of devices manufactured at Boston facility

Integra LifeSciences is poised to take a financial hit totaling tens of millions of dollars following recent voluntary recalls. 

Initiated on May 22, the recalls pertain to all soft tissue repair products manufactured at the company's Boston facility over the last five years. Integra made the move following an internal investigation that revealed excess levels of endotoxins in the products. Deviations from the recommended specifications could cause immune responses that trigger postoperative fevers in patients, the company stated. 

Production of Integra’s SurgiMend, PriMatrix, Revize and TissueMend products has been temporarily halted due to the recalls, but the company said it has not received any customer complaints. 

“Although there is no specific indication of any reported product complaints related to high endotoxin levels, the Company, in accordance with its commitment to patient safety and product quality, has decided to initiate the voluntary recall and extend the temporary halt of manufacturing at its Boston facility to implement additional detection and quality controls,” the recall reads. “The company expects to resume manufacturing at its Boston facility following implementation of such controls.” 

The affected products manufactured at the Boston facility represent approximately 5% of Integra’s consolidated revenues. If production remains sidelined for the rest of 2023, Integra estimates that its earnings will be negatively impacted by approximately $60 million, as it anticipates the need for additional testing and validation beyond 2023. 

The company anticipates providing an updated assessment of its full-year guidance during their second quarter 2023 financial earnings conference call. 

To learn more, click here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

American College of Cardiology President B. Hadley Wilson, MD, discussed why the ACC and other leading cardiology groups are so eager to create a new, independent medical board. This has been a long-term goal for many years, he said, and now it may become a reality. 

Last week brought the latest in an occasional series of conversations on AI between governmental leaders and Big Tech honchos.

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 

Trimed Popup
Trimed Popup